➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
Baxter
Dow
Medtronic
AstraZeneca

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

NEOMYCIN SULFATE Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Neomycin Sulfate, and what generic alternatives are available?

Neomycin Sulfate is a drug marketed by Bristol Myers Squibb, Lannett, Lannett Co Inc, Lilly, Nostrum Labs Inc, Roxane, Sandoz, Teva, Xgen Pharms, Bausch And Lomb, Pharmafair, Alcon Pharms Ltd, Fougera, and Pharmaderm. and is included in twenty NDAs.

The generic ingredient in NEOMYCIN SULFATE is neomycin sulfate; triamcinolone acetonide. There are nineteen drug master file entries for this compound. Additional details are available on the neomycin sulfate; triamcinolone acetonide profile page.

Drug patent expirations by year for NEOMYCIN SULFATE
Recent Clinical Trials for NEOMYCIN SULFATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Emory UniversityPhase 4
Ache Laboratorios Farmaceuticos S.A.Phase 3
European CommissionPhase 2

See all NEOMYCIN SULFATE clinical trials

Pharmacology for NEOMYCIN SULFATE
Medical Subject Heading (MeSH) Categories for NEOMYCIN SULFATE

US Patents and Regulatory Information for NEOMYCIN SULFATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol Myers Squibb NEOMYCIN SULFATE neomycin sulfate TABLET;ORAL 060365-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Fougera NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE neomycin sulfate; triamcinolone acetonide OINTMENT;TOPICAL 062608-001 May 23, 1986 DISCN No No   Start Trial   Start Trial   Start Trial
Sandoz NEOMYCIN SULFATE neomycin sulfate TABLET;ORAL 061586-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Lilly NEOMYCIN SULFATE neomycin sulfate TABLET;ORAL 060385-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Alcon Pharms Ltd NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE dexamethasone sodium phosphate; neomycin sulfate SOLUTION/DROPS;OPHTHALMIC 062714-001 Jul 21, 1986 DISCN No No   Start Trial   Start Trial   Start Trial
Pharmafair NEOMYCIN SULFATE, POLYMYXIN B SULFATE & HYDROCORTISONE hydrocortisone; neomycin sulfate; polymyxin b sulfate SUSPENSION/DROPS;OTIC 062617-001 Sep 18, 1985 DISCN No No   Start Trial   Start Trial   Start Trial
Teva NEOMYCIN SULFATE neomycin sulfate TABLET;ORAL 060304-001 Approved Prior to Jan 1, 1982 AA RX No Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
Moodys
Medtronic
McKinsey
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.